Amplified Sciences Secures Exclusive Patent License from UCSF for Cutting-Edge Diagnostic Technology
West Lafayette, Ind. (June 23, 2025) – Amplified Sciences announced today that it has secured an exclusive global license to a patent from the University of California, San Francisco (UCSF) that helps enable PanCystPro, the company’s first product offered as a Lab Developed Test in their CLIA laboratory.
PanCystPro helps risk stratify patients diagnosed with pancreatic cystic lesions who are at higher risk of developing pancreatic cancer. This multi-analyte test leverages a novel protease turnover assay for gastricsin, an enzyme that is atypically found in the pancreas thus providing biological insight into the cyst’s potential for malignancy. The assay represents a new method of targeting enzymes as biomarkers in precision medicine.
